Yijing Investment

Yijing Investment

Yijing Capital was founded in 2015 and officially launched operations in 2017 out of Shanghai. The firm frames its strategy around the principle of “global vision, value investment,” targeting companies at the intersection of frontier technology and life sciences. While the firm does not publicly identify its founding principals or investment committee, its disclosed footprint spans advanced computing, autonomous mobility, biopharmaceuticals, and next-generation medical devices — a concentration that suggests a deliberate thesis rather than generalist capital. Yijing deploys equity across early-stage, expansion, and late-stage venture rounds, often participating in follow-on financings within its core positions. In frontier technology, its disclosed portfolio includes Leapmotor in electric vehicles, Biren Technology in GPUs, Lightelligence in silicon photonics for artificial intelligence, Silang Technology in processor architecture, Qianxun Spatial Intelligence in high-precision positioning, and Yixin Communication in cellular IoT chips. On the life sciences side, the firm has backed CDMO OPM Biosciences, oncology-focused Tyligand Bioscience, radiopharmaceutical developer Jinghe Bio, and the CAR-T company Oricell, which closed a $70 million C1 round in January 2026. Geographically, Yijing operates from a single Shanghai office but sources deals across China, with portfolio companies headquartered in Shanghai, Beijing, Hangzhou, and Wuxi. Since its launch, Yijing reports that nine portfolio companies have gone public and seven more have attained unicorn status. The landmark liquidity event in the recent period is the April 2026 Hong Kong listing of Lightelligence, a company Yijing backed across multiple private rounds and which achieved a first-day market capitalization reflecting the global scarcity of pure-play AI photonic chip companies. The office is located at 2603 Century Link Tower, 1198 Century Avenue in Shanghai's Pudong district, and total disclosed deployment exceeds RMB 10 billion (per the firm’s website, 2026). Yijing operates without a visible public-facing investment team or any disclosed external limited partners — a structure that, in China’s market, often indicates a firm backed by a single ultra-high-net-worth family or a closed group of entrepreneurs running what is effectively a family-office-style vehicle wearing an asset-manager label. The absence of named decision-makers alongside concentrated multi-round commitments to the same companies points to a governance model where capital allocation and board-level influence sit with a very small, private circle, making Yijing structurally distinct from both brand-name Chinese VC franchises and open-ended funds of funds.